Metagenomi Therapeutics (MGX) Accumulated Depreciation (2023 - 2025)
Metagenomi Therapeutics (MGX) posted quarterly Accumulated Depreciation of $16.0 million for Q4 2025, up 41.64% year-over-year from $11.3 million in Q4 2024, and up 41.64% quarter-over-quarter from $11.3 million in Q4 2024.
Metagenomi Therapeutics (MGX) Accumulated Depreciation (2023 - 2025) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Accumulated Depreciation for 3 consecutive years, with $16.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Accumulated Depreciation rose 41.64% year-over-year to $16.0 million; the TTM figure through Dec 2025 stood at $16.0 million (up 41.64% YoY), while the FY2025 annual figure was $16.0 million, up 41.64% from the prior year.
- Accumulated Depreciation advanced to $16.0 million in Q4 2025 per MGX's latest filing, from $11.3 million in the prior quarter.
- Across five years, Accumulated Depreciation topped out at $16.0 million in Q4 2025 and bottomed at $6.4 million in Q4 2023.
- Historically, Accumulated Depreciation has averaged $11.2 million across 3 years, with a median of $11.3 million in 2024.
- Annual changes were most pronounced in 2024 — Accumulated Depreciation soared 75.15% — and 2025, when it surged 41.64%.
- Metagenomi Therapeutics' Accumulated Depreciation stood at $6.4 million in 2023, then jumped by 75.15% to $11.3 million in 2024, then soared by 41.64% to $16.0 million in 2025.
- Business Quant data shows MGX's Accumulated Depreciation at $16.0 million in Q4 2025, $11.3 million in Q4 2024, and $6.4 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Metagenomi Therapeutics | 46.51 Mn | 46.51 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 15.96 Mn |
| Dec 31, 2024 | 11.27 Mn |
| Dec 31, 2023 | 6.43 Mn |